WeVote
Log In

Bill

Bill

HB 330

An Act amending Title 71 (State Government) of the Pennsylvania Consolidated Statutes, providing for improper payments; providing for participation in Do-Not-Pay Initiative; and imposing a penalty.

2025-2026 Regular Session Introduced by Seth Grove and 6 co-sponsors

HB 330 broadens the Controlled Substances Act to explicitly add and regulate emergent synthetic opioids, cannabinoids, cathinones, nitazene and benzodiazepine analogs, and related

Referred to Appropriations
0
WeVote Research Nonpartisan
Bill Summary · HB 330

HB 330 — Controlled Substances Act — Updates

Status: Regular Message Sent to Senate
Introduced: (Bill record) Nov 12, 2024 — (active session activity) early 2025
Subject areas: Controlled substances, public health, law enforcement, pharmaceuticals

Main purpose / intent

HB 330 updates the state's Controlled Substances Act by expanding and clarifying the statutory listings and structural definitions of multiple classes of synthetic and designer drugs. The bill is intended to capture newly emergent opioid analogs, synthetic cannabinoids, substituted cathinones, benzodiazepine analogs, and related novel psychoactive substances so they can be regulated and prosecuted under existing scheduling/possession/manufacturing laws.

Key provisions

  • Amends G.S. 90‑89 to expand enumerated controlled substances and classes, including (examples drawn from the bill text):
    • Numerous U-series opioids and related AP‑237/AP‑238 entries (additional U‑47700 variants and related analogs).
    • Expanded listing of fentanyl derivatives (adds specific fluorinated and butyryl/isobutyryl variants and language covering structural substitutions).
    • Adds a new subdivision defining and criminalizing “nitazene derivatives” (the N‑substituted benzimidazole structural class) with detailed structural-language to capture many analogs.
    • Expands the definition/listing of synthetic cannabinoids (including indole carboxamides and related structural families).
    • Revises the substituted cathinone definition (broadening the structural criteria; exempts bupropion).
    • Adds bromazolam (a benzodiazepine analog) to the controlled list.
  • Specifies that listed compounds (and their isomers, salts, esters, ethers) are controlled “unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the U.S. FDA.”
  • Retains existing scheduling framework and penalties by incorporating these substances into the statutory schedule language.

Who or what would be affected

  • Law enforcement and prosecutors: broader statutory authority to investigate, charge, and prosecute trafficking/possession/manufacturing of many recently developed designer drugs.
  • Public health and treatment providers: potential increases in enforcement actions and evidence handling; also potential benefits from clearer statutory tools to target dangerous illicit compounds fueling overdoses.
  • Researchers, legitimate manufacturers, and regulated pharmaceutical entities: the bill includes carve-outs for FDA‑approved pharmaceutical products and for certain research uses, but expanded statutory breadth may require additional compliance checks for laboratories and manufacturers handling related chemical classes.
  • Crime labs and toxicology services: may need capacity/analytical updates to identify and confirm additional listed compounds.

Procedural / timeline notes

  • The bill text and committee substitute(s) were active in early 2025 (committee activity and substitute versions appear in March 2025).
  • Recorded procedural actions indicate committee consideration, a committee substitute, and placement on a General State Calendar; status shown as “Regular Message Sent to Senate.” (Exact committee names and dates vary across versions; as of the latest bill record provided, the measure has advanced from initial readings and committee work toward consideration by the second chamber.)
  • No state fiscal note specific to this NC bill was included in the provided materials; potential fiscal impacts (lab testing, prosecution, corrections) are not quantified in the text provided.

Practical considerations / likely impacts

  • Strengthens statutory coverage of emergent synthetic opioids (e.g., nitazenes, fentanyl analogs) and other designer drugs to reduce legal loopholes used by illicit suppliers.
  • Could require investment in forensic/analytical capacity and training for law enforcement and public-safety labs to identify and process the newly enumerated substances.
  • May raise questions for medical/research institutions about compliance; the bill’s exceptions for FDA‑approved products and supervised medical or research use are important but may require administrative clarification.

If you want, I can:
- Extract and list the specific chemical names and structural classes the bill adds (from the bill text), or
- Draft a short one‑page briefing tailored to prosecutors, public health officials, or forensic labs describing operational impacts and next steps.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.